NYSEARCA:PJP Invesco Pharmaceuticals ETF (PJP) Price, Holdings, & News $124.09 -0.65 (-0.52%) Closing price 09/11/2026 04:10 PM EasternExtended Trading$124.11 +0.02 (+0.02%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About Invesco Pharmaceuticals ETF (NYSEARCA:PJP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PJP alerts:Sign Up Key Stats Today's Range$124.09▼$125.9950-Day Range$115.91▼$131.6452-Week Range$90.01▼$131.68Volume26,403 shsAverage Volume35,987 shsMarket Capitalization$476.51 millionAssets Under Management$544.86 millionDividend Yield0.85%Net Expense Ratio0.57%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund normally invests at least 90% of its total assets in common stocks that consists of the Index. The Fund's investment advisor is Invesco PowerShares Capital Management LLC. Read More Invesco Pharmaceuticals ETF ExpensesTypePJPHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.55%0.57%0.50%0.53%Other Expenses0.07%0.52%0.53%0.60%0.54%Total Expense0.57%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%Net Expense0.57%0.58%0.63%0.57%0.60% Receive PJP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PJP ETF News HeadlinesInvesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better ProfitsSeptember 8, 2026 | finance.yahoo.comFHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?August 23, 2026 | fool.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 12 at 1:00 AM | Golden Portfolio (Ad)These New Drugs Could Fuel Fresh Highs for Biotech and Pharma StocksAugust 7, 2026 | barrons.comInvesco Pharmaceuticals ETFJuly 31, 2026 | money.usnews.comAs Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?July 22, 2026 | fool.comSee More Headlines PJP ETF - Frequently Asked Questions How have PJP shares performed this year? Invesco Pharmaceuticals ETF's stock was trading at $104.54 at the beginning of the year. Since then, PJP stock has increased by 18.7% and is now trading at $124.09. Who are Invesco Pharmaceuticals ETF's major shareholders? Invesco Pharmaceuticals ETF's top institutional shareholders include Trilogy Capital Inc. (0.51%), Secure Asset Management LLC (0.09%), MOR Wealth Management LLC (0.05%) and Integrated Wealth Concepts LLC (0.01%). How do I buy shares of Invesco Pharmaceuticals ETF? Shares of PJP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Pharmaceuticals ETF investors own include NVIDIA (NVDA), Meta Platforms (META), Walt Disney (DIS), Affirm (AFRM), Advanced Micro Devices (AMD), Netflix (NFLX) and Pfizer (PFE). Fund Details IssuerInvesco Fund NameInvesco Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PJP Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Pharmaceutical Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings29 Fund Statistics Assets Under Management$544.86 million Average Daily Volume$30.21 thousand Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest28,773 shs Miscellaneous Outstanding Shares3,840,000Beta0.45 Creation Unit10,000 Creation Fee$500.00 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report Top 10 PJP HoldingsAbbott Laboratories (NYSE:ABT)Holding Weight: 5.77%Amgen (NASDAQ:AMGN)Holding Weight: 5.72%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 5.51%AbbVie (NYSE:ABBV)Holding Weight: 5.33%Johnson & Johnson (NYSE:JNJ)Holding Weight: 5.17%Eli Lilly and Company (NYSE:LLY)Holding Weight: 4.90%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.84%Pfizer (NYSE:PFE)Holding Weight: 4.81%Corcept Therapeutics (NASDAQ:CORT)Holding Weight: 4.72%Travere Therapeutics (NASDAQ:TVTX)Holding Weight: 3.71%Full Holdings DetailsPJP Sector ExposurePJP Industry Exposure This page (NYSEARCA:PJP) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.